VTVT
vTv Therapeutics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-28/100
Last price
29.75
▼ 0.58 (1.91%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
30.50
Prev close
30.33
Day high
30.50
Day low
29.55
Volume
27.93K
Market cap
$118.74M
P/E (TTM)
—
52W range
19.50 – 44.00
Day trading desk
Gap from prior close
+0.56%
Prior close 30.33
VWAP
30.12
-1.23% from price
Relative volume
0.35×
Quiet session
Session range
3.21%
29.55 – 30.50
Position in range
21%
Near session low
ATR (14D)
1.24
4.18% of price
Prior day high
31.56
PDH
Prior day low
30.29
PDL
Bid / ask spread
—
Quote not published
Session volume
24.54K
Avg 69.23K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.10%
-1.8%
1M
-9.96%
-11.1%
3M
-13.28%
-17.8%
6M
-21.49%
-39.7%
YTD
-24.91%
-39.2%
1Y
+24.61%
+8.2%
3Y
+57.06%
-25.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VTVT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
4.82M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 22, 25 | AKKARAJU SRINIVAS Director |
STOCK | 106.00K | $2.35M | Indirect |
| Sep 3, 25 | BAKER BROS ADVISORS, L.P. Unknown |
STOCK | 51.00K | $0 | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AKKARAJU SRINIVAS |
Director | — | Stock Award(Grant) |
BAKER BROS ADVISORS, L.P. |
Unknown | — | Stock Award(Grant) |
Fundamentals
Market cap$118.74M
Enterprise value$286.47M
Revenue (TTM)$36.84M
Gross profit$8.16M
EBITDA$-9.24M
Net income$-4.76M
EPS (TTM)$-0.72
Free cash flow$674.38K
Total cash$86.64M
Total debt$0
Book value / share$6.34
Shares outstanding3.95M
Float2.16M
Short % of float6.68%
Dividend yield0.00%
Beta (5Y)0.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.39
PEG ratio—
Price / sales—
Price / book4.74
EV / revenue7.78
EV / EBITDA-30.99
Gross margin22.16%
Operating margin-25.11%
Profit margin-12.91%
Return on equity-15.80%
Return on assets-10.14%
Debt / equity—
Current ratio12.48
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $1.02M | $0 | $2.02M | -100.0% |
| Operating revenue | $0 | $1.02M | $0 | $2.02M | -100.0% |
| Research & development | $17.86M | $11.55M | $13.60M | $12.36M | +54.7% |
| Selling, general & admin | $14.95M | $13.65M | $11.91M | $12.20M | +9.5% |
| Total operating expense | $32.81M | $25.20M | $25.50M | $24.56M | +30.2% |
| Operating income | -$32.81M | -$24.18M | -$25.50M | -$22.54M | -35.7% |
| Net interest income | $1.86M | $1.56M | $459.00K | $337.00K | +19.1% |
| Pre-tax income | -$31.08M | -$22.61M | -$25.97M | -$24.87M | -37.5% |
| Tax provision | $0 | $100.00K | $0 | $200.00K | -100.0% |
| Net income | -$26.97M | -$18.46M | -$20.25M | -$19.16M | -46.1% |
| Net income to common | -$26.97M | -$18.46M | -$20.25M | -$19.16M | -46.1% |
| Basic EPS | -3.20 | -3.20 | -9.71 | -10.40 | 0.0% |
| Diluted EPS | -3.20 | -3.20 | -9.71 | -10.40 | 0.0% |
| EBIT | -$31.07M | -$22.61M | -$25.95M | -$24.86M | -37.5% |
| EBITDA | -$31.06M | -$22.52M | -$25.86M | -$24.77M | -37.9% |
| Basic shares | 8.42M | 5.77M | 2.08M | 1.87M | +46.0% |
| Diluted shares | 8.42M | 5.77M | 2.08M | 1.87M | +46.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $88.93M | $36.75M | $9.45M | $12.13M | — | +142.0% |
| Cash & short-term investments | $88.93M | $36.75M | $9.45M | $12.13M | — | +142.0% |
| Accounts receivable | — | $62.00K | $102.00K | $173.00K | $57.00K | — |
| Total current assets | $89.89M | $38.11M | $10.66M | $27.09M | — | +135.9% |
| Property, plant & equipment | — | $153.00K | $361.00K | $556.00K | $680.00K | — |
| Total assets | $89.90M | $38.27M | $11.02M | $33.24M | — | +134.9% |
| Total current liabilities | $6.64M | $5.20M | $10.62M | $7.71M | — | +27.8% |
| Current debt | — | — | $191.00K | $224.00K | $256.00K | — |
| Total debt | $0 | $169.00K | $529.00K | $716.00K | — | -100.0% |
| Total liabilities | $25.46M | $23.96M | $29.57M | $27.40M | — | +6.2% |
| Retained earnings | -$326.69M | -$299.72M | -$281.04M | -$265.52M | — | -9.0% |
| Shareholder equity | $64.44M | $12.20M | -$24.68M | -$10.74M | — | +428.2% |
| Working capital | $83.25M | $32.92M | $38.00K | $19.39M | — | +152.9% |
| Net tangible assets | $64.44M | $12.20M | -$24.68M | -$10.74M | — | +428.2% |
| Shares issued | 3.94M | 2.61M | 2.08M | 2.04M | — | +50.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$31.08M | -$22.70M | -$25.97M | -$25.07M | -36.9% |
| Depreciation & amortisation | $16.00K | $89.00K | $90.00K | $92.00K | -82.0% |
| Stock-based compensation | $3.77M | $2.76M | $1.58M | $1.27M | +36.9% |
| Change in working capital | $1.89M | -$5.44M | $4.39M | $5.38M | +134.8% |
| Operating cash flow | -$25.25M | -$25.31M | -$19.08M | -$16.02M | +0.2% |
| Capital expenditure | — | — | — | -$21.00K | — |
| Investing cash flow | $0 | $0 | $4.40M | -$21.00K | — |
| Financing cash flow | $77.44M | $52.61M | $12.00M | $14.75M | +47.2% |
| Free cash flow | -$25.25M | -$25.31M | -$19.08M | -$16.04M | +0.2% |
| End cash position | $88.93M | $36.75M | $9.45M | $12.13M | +142.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $36.84M | $0 | $0 | $0 | -100.0% |
| Operating revenue | $0 | $36.84M | $0 | $0 | $0 | -100.0% |
| Research & development | $8.77M | $8.98M | $3.91M | $7.02M | $4.10M | -2.3% |
| Selling, general & admin | $5.16M | $4.60M | $3.98M | $3.68M | $3.62M | +12.2% |
| Total operating expense | $13.93M | $13.58M | $7.88M | $10.70M | $7.72M | +2.6% |
| Operating income | -$13.93M | $23.26M | -$7.88M | -$10.70M | -$7.72M | -159.9% |
| Net interest income | $812.00K | $838.00K | $864.00K | $394.00K | $275.00K | -3.1% |
| Pre-tax income | -$13.05M | $24.13M | -$7.14M | -$10.35M | -$7.38M | -154.1% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$13.05M | $24.13M | -$7.14M | -$8.70M | -$6.05M | -154.1% |
| Net income to common | -$13.05M | $24.13M | -$7.14M | -$8.70M | -$6.05M | -154.1% |
| Basic EPS | -1.05 | 1.94 | -0.58 | -1.08 | -0.92 | -154.1% |
| Diluted EPS | -1.05 | 1.65 | -0.58 | -1.08 | -0.92 | -163.6% |
| EBIT | -$13.93M | $23.26M | -$7.14M | -$10.34M | -$7.72M | -159.9% |
| EBITDA | -$13.93M | $23.26M | -$7.13M | -$10.34M | -$7.72M | -159.9% |
| Basic shares | 12.41M | 12.41M | 12.41M | 8.06M | 6.59M | +0.0% |
| Diluted shares | 12.41M | 14.63M | 12.41M | 8.06M | 6.59M | -15.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $86.64M | $98.09M | $88.93M | $98.50M | $25.92M | — | -11.7% |
| Cash & short-term investments | $86.64M | $98.09M | $88.93M | $98.50M | $25.92M | — | -11.7% |
| Total current assets | $87.59M | $98.81M | $89.89M | $99.46M | $26.37M | — | -11.4% |
| Property, plant & equipment | — | — | — | $38.00K | $74.00K | $111.00K | — |
| Total assets | $87.59M | $98.81M | $89.90M | $99.49M | $26.45M | — | -11.4% |
| Total current liabilities | $7.02M | $6.88M | $6.64M | $10.16M | $5.29M | — | +2.0% |
| Current debt | — | — | — | $328.00K | — | — | — |
| Total debt | — | — | $0 | $360.00K | $79.00K | $125.00K | — |
| Total liabilities | $8.96M | $8.85M | $25.46M | $28.95M | $24.04M | — | +1.2% |
| Retained earnings | -$315.61M | -$302.56M | -$326.69M | -$319.55M | -$310.86M | — | -4.3% |
| Shareholder equity | $78.63M | $89.96M | $64.44M | $70.54M | $2.76M | — | -12.6% |
| Working capital | $80.57M | $91.93M | $83.25M | $89.29M | $21.08M | — | -12.4% |
| Net tangible assets | $78.63M | $89.96M | $64.44M | $70.54M | $2.76M | — | -12.6% |
| Shares issued | 3.94M | 3.94M | 3.94M | 3.94M | 2.62M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$13.05M | $24.13M | -$7.14M | -$10.35M | -$7.38M | — | -154.1% |
| Depreciation & amortisation | $1.00K | $1.00K | $2.00K | $2.00K | $3.00K | — | 0.0% |
| Stock-based compensation | $1.73M | $1.39M | $1.02M | $1.01M | $930.00K | — | +24.4% |
| Change in working capital | -$53.00K | -$16.34M | -$3.26M | $4.07M | $1.42M | — | +99.7% |
| Operating cash flow | -$11.44M | $9.15M | -$9.25M | -$5.22M | -$5.09M | — | -225.0% |
| Financing cash flow | — | — | -$321.00K | $77.80M | -$42.00K | $0 | — |
| Free cash flow | -$11.44M | $9.15M | -$9.25M | -$5.22M | -$5.09M | — | -225.0% |
| End cash position | $86.64M | $98.09M | $88.93M | $98.50M | $25.92M | — | -11.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.09 | -1.05 | +3.2% |
| Mar 2026 | 0.21 | 1.65 | +685.7% |
| Dec 2025 | -1.09 | -0.58 | +46.7% |
| Sep 2025 | -0.98 | -1.08 | -10.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.18 | 4 | $0 | 0.0% |
| Next quarter | -1.17 | 4 | $0 | 0.0% |
| Current year | -2.22 | 4 | $29.48M | 0.0% |
| Next year | -4.70 | 6 | $0 | -100.0% |
Analyst targets & ownership
Mean target$54.71
High target$67.00
Low target$42.00
Implied upside83.91%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy0 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders38.83%
Held by institutions40.75%
Institutions holding52
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
30.57
-2.67% from price
SMA 20
31.04
-3.24% from price
SMA 50
32.05
-6.32% from price
SMA 100
32.92
-9.64% from price
SMA 200
34.48
-12.90% from price
EMA 12
30.75
-3.24% from price
EMA 26
31.26
-4.84% from price
EMA 50
31.86
-6.62% from price
RSI (14)
41.5
Neutral
MACD (12,26,9)
-0.52
Hist -0.02
ATR (14)
1.24
4.14% of price
Realised vol 30D
32.0%
Annualised
Bollinger upper
32.65
20, 2σ
Bollinger lower
29.42
20, 2σ
50 / 200 cross
Death
32.05 vs 34.48
Trend bias
Below 200
-12.90%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.05
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
32.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.1%
Peak to trough
Max drawdown 5Y
-87.8%
Peak to trough
ATR 14
1.24
4.14% of price
Beta (reported)
0.21
5Y monthly, from filing
Short interest
Shares short
160.31K
Prior 166.00K
Change vs prior
-3.4%
Shorts covering
% of float
6.68%
Normal
% of shares out
4.05%
Against total outstanding
Days to cover
3.4
Liquid
Float
2.16M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 16, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 12, 26 | Evercore ISI Group | INITIATED | — | Outperform |
| Mar 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 27, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 23, 26 | Roth Capital | INITIATED | — | Buy |
| Jan 5, 26 | TD Cowen | INITIATED | — | Buy |
| Dec 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 19, 25 | BTIG | INITIATED | — | Buy |
| Aug 13, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 9, 25 | HC Wainwright & Co. | INITIATED | — | Buy |
| Dec 9, 24 | Alliance Global Partners | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:40
Split dateNov 21, 2023
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-29
Proxy Statements
DEFA14A · 2026-06-10
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-03-10
Corporate Changes & Voting Matters
8-K · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2026-02-02
Headlines
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
GlobeNewswire · 18h ago
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
GlobeNewswire · 2d ago
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 21d ago
vTv Therapeutics to Participate in September Investor Conferences
GlobeNewswire · 35d ago
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 48d ago
VTv Therapeutics: Q2 Earnings Snapshot
Associated Press · 62d ago
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 62d ago
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 70d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.